DMRA Earnings Damora Therapeutics, Inc.
Reported diluted EPS by fiscal period (SEC EDGAR). Chart & overview →
1–19 of 19
| Q1 2026 | 2026-03-31 | -0.62 | 2026-05-12 | 10-Q |
| FY 2025 | 2025-12-31 | 3.98 | 2026-03-19 | 10-K |
| Q3 2025 | 2025-09-30 | -6.88 | 2025-11-06 | 10-Q |
| Q2 2025 | 2025-06-30 | -4.51 | 2025-08-05 | 10-Q |
| Q1 2026 | 2025-03-31 | -1.92 | 2026-05-12 | 10-Q |
| FY 2025 | 2024-12-31 | -18.53 | 2026-03-19 | 10-K |
| Q3 2025 | 2024-09-30 | -13.30 | 2025-11-06 | 10-Q |
| Q2 2025 | 2024-06-30 | -9.97 | 2025-08-05 | 10-Q |
| Q1 2025 | 2024-03-31 | -5.05 | 2025-05-08 | 10-Q |
| FY 2024 | 2023-12-31 | -36.08 | 2025-03-19 | 10-K |
| Q3 2024 | 2023-09-30 | -30.19 | 2024-11-01 | 10-Q |
| Q2 2024 | 2023-06-30 | -0.91 | 2024-08-12 | 10-Q |
| Q1 2024 | 2023-03-31 | -0.51 | 2024-04-29 | 10-Q |
| FY 2023 | 2022-12-31 | -2.43 | 2024-03-08 | 10-K |
| Q3 2023 | 2022-09-30 | -1.88 | 2023-11-06 | 10-Q |
| Q2 2023 | 2022-06-30 | -1.34 | 2023-07-31 | 10-Q |
| Q1 2023 | 2022-03-31 | -0.67 | 2023-04-28 | 10-Q |
| FY 2022 | 2021-12-31 | -2.05 | 2023-03-09 | 10-K |
| Q3 2022 | 2021-09-30 | -1.52 | 2022-11-08 | 10-Q |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Informational only — not financial advice.